Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study was the non-interventional, retrospective study aimed to assess the effectiveness and safety of omalizumab in children with allergic asthma in China, and described patient profiles and treatment patterns of omalizumab in real-world practice.
This non-interventional, retrospective study aimed to assess the effectiveness and safety of omalizumab in children with allergic asthma in China, and described patient profiles and treatment patterns of omalizumab in real-world practice. This study was designed to use secondary data from medical charts of 25 hospitals. Medical records were reviewed to collect information such as demographics, clinical characteristics, treatment patterns, effectiveness, and AEs for retrospective analysis. Patients with allergic asthma aged 6 -<12 years treated with omalizumab from July 6, 2018 to September 30, 2020 were identified for medical chart extraction.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Omalizumab | Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Omalizumab | Drug | Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients who responded to omalizumab | The responders were defined as patients with:
| After 4-6 months of treatment (Between July 6, 2018 to September 30, 2020) |
| Measure | Description | Time Frame |
|---|---|---|
| Number of adverse events and serious adverse events | To evaluate safety of omalizumab among children with allergic asthma in China. | Throughout the study, approximately 2 years |
| Proportion of patients with positive investigator's Global Evaluation of Treatment Effectiveness (GETE) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with allergic asthma treated with omalizumab from July 6, 2018 to September 30, 2020 were identified for medical chart extraction
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | East Hanover | New Jersey | 07936-1080 | United States |
Not provided
| Label | URL |
|---|---|
| Results for CIGE025BCN01 from the Novartis Clinical Trials Results Database | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069444 | Omalizumab |
| ID | Term |
|---|---|
| D000888 | Antibodies, Anti-Idiotypic |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
Not provided
Not provided
Not provided
Not provided
Not provided
Positive investigator's GETE is defined as restrospectively evaluated GETE are Excellent or Good. |
| After 4-6 months of treatment (Between July 6, 2018 to September 30, 2020) |
| Change from baseline in moderate-to-severe Asthma exacerbation | Moderate-to-severe asthma exacerbation is defined as worsening of asthma symptoms requiring doubling of baseline ICS dose and/or treatment with rescue systemic corticosteroids for ≥ 3 days. | Baseline, after 4-6 months of treatment (Between July 6, 2018 to September 30, 2020) |
| Change from baseline in severe Asthma exacerbation | Severe asthma exacerbation is defined as requiring ER admission /hospitalization/ICU admission/mechanical ventilation with systemic corticosteroids for ≥ 3 days. | Baseline, after 4-6 months of treatment (Between July 6, 2018 to September 30, 2020) |
| Average change from baseline in daily inhaled corticosteroids (ICS) dose | The dosage of inhaled corticosteroids (ICS) was reported to evaluate the effectiveness of omalizumab among children aged 6 -<12 years with allergic asthma in China. | Baseline, after 4-6 months of treatment (Between July 6, 2018 to September 30, 2020) |
| Average change from baseline in daily oral corticosteroids (OCS) dose | The dosage of oral corticosteroids (OCS) was reported to evaluate the effectiveness of omalizumab among children aged 6 -<12 years with allergic asthma in China. | Baseline, after 4-6 months of treatment (Between July 6, 2018 to September 30, 2020) |
| Percentage of patients that successfully stopped Oral Corticosteroids | Percentage of patients that successfully stopped Oral Corticosteroids after 4 to 6 months of treatment were reported | After 4-6 months of treatment (Between July 6, 2018 to September 30, 2020) |
| Change from baseline in Lung function using Forced Expiratory Volume in 1 Second (FEV1) | Lung function was assessed using Forced Expiratory Volume in 1 Second (FEV1) to evaluate the effectiveness of omalizumab among children aged 6 -<12 years with allergic asthma in China. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. | Baseline, after 4-6 months of treatment (Between July 6, 2018 to September 30, 2020) |
| Change from baseline in FEV1% pred | Ratio of patient's actual results compared to predicted normal values, expressed as a percentage. | Baseline, after 4-6 months of treatment (Between July 6, 2018 to September 30, 2020) |
| Change from baseline in FEV1/FVC | The FEV1/FVC ratio indicates how much air you can forcefully exhale. | Baseline, after 4-6 months of treatment (Between July 6, 2018 to September 30, 2020) |
| Change from baseline in Peak Expiratory Flow (PEF) | Peak Expiratory Flow (PEF) is an objective measure of how well the lungs are functioning and can measure airway narrowing. | Baseline, after 4-6 months of treatment (Between July 6, 2018 to September 30, 2020) |
| Change from baseline in Maximal mid-expiratory flow (MMEF) | Maximal mid-expiratory flow (MMEF) is a spirometric parameter reflecting airflow of large and small airways. | Baseline, after 4-6 months of treatment (Between July 6, 2018 to September 30, 2020) |
| Number of patients who received the recommended dosage instructions during the identification period | To describe the treatment pattern of omalizumab among children with allergic asthma in China. | Throughout the study, approximately 2 years |
| Median time to discontinuation of the treatment | To describe the treatment pattern of Xolair among children with allergic asthma in China. | Throughout the study, approximately 2 years |
| Percentage of patients using Omalizumab for more than 4, 16, 24 and 52 weeks | To describe the treatment pattern of omalizumab among children with allergic asthma in China. | Week 4, 16, 24 and 52 (Between July 6, 2018 to September 30, 2020) |
| Number of patients who discontinued omalizumab | To describe the treatment pattern of omalizumab among children with allergic asthma in China. | Throughout the study, approximately 2 years |
| D001798 |
| Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D012712 | Serum Globulins |
| D005916 | Globulins |